Pharmacokinetics of a Sustained Release Formulation of Buprenorphine After Intramuscular and Subcutaneous Administration to American Kestrels (Falco sparverius)

2017 ◽  
Vol 31 (2) ◽  
pp. 102-107 ◽  
Author(s):  
David Sanchez-Migallon Guzman ◽  
Heather K. Knych ◽  
Glenn H. Olsen, ◽  
Joanne R. Paul-Murphy
Keyword(s):  
Sustained Release ◽  
Subcutaneous Administration ◽  
Falco Sparverius ◽  
Release Formulation ◽  
Sustained Release Formulation ◽  
American Kestrels

Pharmacokinetics of a Sustained-release Formulation of Meloxicam After Subcutaneous Administration to Hispaniolan Amazon Parrots (Amazona ventralis)

2017 ◽  
Vol 31 (3) ◽  
pp. 219-224 ◽  
Author(s):  
David Sanchez-Migallon Guzman ◽  
Michael H. Court ◽  
Zhaohui Zhu, ◽  
Noémie Summa ◽  
Joanne R. Paul-Murphy
Keyword(s):  
Sustained Release ◽  
Subcutaneous Administration ◽  
Release Formulation ◽  
Sustained Release Formulation

Development of an injectable sustained-release formulation of morphine: antinociceptive properties in rats

1998 ◽  
Vol 32 (3) ◽  
pp. 270-275 ◽  
Author(s):  
R. A. R. Tasker ◽  
B. J. Connell ◽  
S. J. Ross ◽  
C. M. Elson
Keyword(s):  
Sustained Release ◽  
Subcutaneous Administration ◽  
Opioid Analgesics ◽  
Morphine Sulphate ◽  
Release Formulation ◽  
Sustained Release Formulation ◽  
Sterile Saline ◽  
Long Term Storage ◽  
Chitosan Gel

The antinociceptive actions of morphine incorporated into an injectable chitosan-based gel were investigated in rats. Subcutaneous administration of 4.8 mg/kg morphine sulphate in a gel composed of N,O-carboxymethylchitosan (NOCC) and chitosan resulted in significant antinociception within 10 min that was maximal at 60 min and persisted for 6 h. In contrast, the same dose of morphine sulphate injected in sterile saline produced maximal responses at 30 min but only persisted for 2 h. NOCC/chitosan gel was easily injectable using a 22 guage needle and appears stable in long-term storage. No local or systemic adverse effects other than morphine-induced sedation were observed either at the time of injection or during the subsequent 48 h. We conclude that gels composed of chitosan and chitosan derivatives are effective matrices for sustained-release formulations of opioid analgesics capable of providing long-lasting antinociception.

▾ Piretanide for hypertension

1985 ◽  
Vol 23 (11) ◽  
pp. 43-44
Keyword(s):  
Glucose Tolerance ◽  
Sustained Release ◽  
Loop Diuretic ◽  
Plasma Potassium ◽  
Release Formulation ◽  
Sustained Release Formulation ◽  
Treatment Of Hypertension

Piretanide is a loop diuretic recently marketed in a sustained-release formulation (Arelix - Hoechst) solely for the treatment of hypertension (rather than as a general diuretic). The manufacturer claims that piretanide has several advantages over the thiazides, including little or no effect on plasma potassium and magnesium, and no impairment of glucose tolerance.

Sign in / Sign up

Export Citation Format

Share Document